TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WITH RO7790121 DEMONSTRATES EARLY CLINICAL RESPONSE AND SYMPTOM IMPROVEMENT – RESULTS FROM THE PHASE 2B TUSCANY-2 TRIAL

Authors
Category Primary study
ConferenceThe 2025 Crohn’s & Colitis Congress®
Year 2025
This article has no abstract
Epistemonikos ID: 321cfa0492933555b888f7ffb6ede63671914881
First added on: Mar 07, 2025